Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes

Published:2019-09-24 Issue:12 Volume:322 Page:1155
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Rosenstock Julio¹²,Kahn Steven E.³⁴,Johansen Odd Erik⁵,Zinman Bernard⁶⁷,Espeland Mark A.⁸,Woerle Hans J.⁹,Pfarr Egon¹⁰,Keller Annett¹⁰,Mattheus Michaela¹⁰,Baanstra David¹¹,Meinicke Thomas¹²,George Jyothis T.¹⁰,von Eynatten Maximilian¹⁰,McGuire Darren K.²,Marx Nikolaus¹³,

Affiliation:

1. Dallas Diabetes Research Center at Medical City, Dallas, Texas

2. University of Texas Southwestern Medical Center, Dallas

3. Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, VA Puget Sound Health Care System, Seattle, Washington

4. University of Washington, Seattle

5. Boehringer Ingelheim Norway KS, Asker, Norway

6. Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada

7. Division of Endocrinology, University of Toronto, Toronto, Canada

8. Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, North Carolina

9. Ulm University, Ulm, Germany.

10. Boehringer Ingelheim International GmbH & Co KG, Ingelheim, Germany

11. Boehringer Ingelheim, Alkmaar, the Netherlands

12. Boehringer Ingelheim International GmbH & Co KG, Biberach, Germany

13. Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Germany

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jama/articlepdf/2751398/jama_rosenstock_2019_oi_190101.pdf

Reference24 articles.

1. Management of hyperglycemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).;Davies;Diabetes Care,2018

2. 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.;Das;J Am Coll Cardiol,2018

3. Long-term trends in antidiabetes drug usage in the U.S.: real-world evidence in patients newly diagnosed with type 2 diabetes.;Montvida;Diabetes Care,2018

4. Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: systematic review and meta-analysis.;Foroutan;Clin Invest Med,2016

5. Emergency hospitalizations for adverse drug events in older Americans.;Budnitz;N Engl J Med,2011

Cited by 439 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of type 2 diabetes;Die Diabetologie;2024-01-30

2. Effects of newer anti-hyperglycemic agents on cardiovascular outcomes in older adults: systematic review and meta-analysis;2024-01-25

3. Reply to: Comment on: Association of sulfonylureas with the risk of dementia: A population‐based cohort study;Journal of the American Geriatrics Society;2024-01-20

4. Heart Failure and Diabetes;Textbook of Diabetes;2024-01-12

5. Ischaemic Heart Disease in Diabetes;Textbook of Diabetes;2024-01-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3